TOMZ experienced a sharp contraction across nearly every financial metric, with revenue declining over 27%, cash falling by roughly 87%, and stockholders' equity eroding by roughly 86% year-over-year.
The near-depletion of cash reserves — from $5.3M to $665K — combined with ongoing negative operating cash flow raises serious questions about the company's near-term liquidity and ability to fund operations without additional financing. The simultaneous decline in accounts receivable and revenue suggests weakening demand for SteraMist products and services, not merely timing differences in collections. Investors should closely monitor whether management pursues equity raises, debt restructuring, or asset sales to bridge the growing funding gap, as the current trajectory is unsustainable without intervention.
Revenue declined meaningfully to $5.6M from $7.7M, while capital expenditures were nearly eliminated — dropping from $108K to just $5K — signaling a company in capital preservation mode rather than growth investment. On the balance sheet, cash fell dramatically to $665K, current assets contracted by roughly 35%, and total assets declined by over 27%, while total debt moderated somewhat from $5.0M to $3.1M, offering limited relief. The overall picture is one of accelerating financial stress: shrinking revenue, a near-exhausted cash cushion, and deeply eroded equity of just $589K collectively point to a business at a critical inflection point that demands close scrutiny from investors.
Capex reduced 95.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Cash declined 87.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Debt reduced 37.3% — deleveraging strengthens balance sheet and reduces financial risk.
Current assets declined 35.5% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 27.4% — asset sales, write-downs, or balance sheet optimization underway.
Revenue softened 27.2% — monitor whether this is cyclical or structural.
Inventory reduced 18.2% — lean inventory management or demand outpacing supply.
Operating cash flow grew 16.9% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →